Novo Nordisk As operates within the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Novo Nordisk As with three other
pharmaceutical manufacturers in Europe:
sales of 14.84 billion Euro [US$16.43 billion]
of which 42%
Lonza Group AG
(5.54 billion Swiss Francs [US$5.68 billion]
of which 56%
was Pharma&Biotech), and
based in the United Kingdom
(£16.60 billion [US$20.17 billion]
of which 100%
During the year ended December of 2018, sales at
Novo Nordisk As were 111.83 billion Danish Kroner (US$16.60 billion).
a very small
increase of 0.1%
versus 2017, when the company's sales were 111.70 billion Danish Kroner.